炎症性关节炎患者口服补充药物的使用:澳大利亚风湿病协会数据库分析。

IF 2.3 Q2 RHEUMATOLOGY International Journal of Rheumatology Pub Date : 2020-06-05 eCollection Date: 2020-01-01 DOI:10.1155/2020/6542965
Ashley Fletcher, Marissa Lassere, Lyn March, Catherine Hill, Graeme Carroll, Claire Barrett, Rachelle Buchbinder
{"title":"炎症性关节炎患者口服补充药物的使用:澳大利亚风湿病协会数据库分析。","authors":"Ashley Fletcher,&nbsp;Marissa Lassere,&nbsp;Lyn March,&nbsp;Catherine Hill,&nbsp;Graeme Carroll,&nbsp;Claire Barrett,&nbsp;Rachelle Buchbinder","doi":"10.1155/2020/6542965","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To describe oral complementary medicine (CM) use in people with inflammatory arthritis, associations with use, and changes in use over time.</p><p><strong>Methods: </strong>Demographic, clinical, and patient-reported outcome data from 5,630 participants with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), and juvenile idiopathic arthritis (JIA) were extracted from the Australian Rheumatology Association Database (ARAD), a national observational database. CM use at entry into ARAD was ascertained for participants recruited between 2002 and 2018. CM was categorised according to the NIH/Cochrane schema (fatty acids, herbs, or supplements). Logistic regression was used to assess associations between demographic characteristics and CM use. Change in CM use between 2006 and 2016 was investigated using a nonparametric test for trend of rate by year.</p><p><strong>Results: </strong>2,156 (38.3%) ARAD participants were taking CM at enrolment (RA: 1,502/3,960 (37.9%), AS: 281/736 (38.2%), PsA: 334/749 (44.6%), and JIA: 39/185 (21.1%)). CM use was more prevalent in women (OR 1.3; 95% CI: 1.13-1.50), those with tertiary education (OR 1.32; 95% CI: 1.13-1.55), private health insurance (OR 1.26; (95% CI: 1.10-1.44), drinking alcohol sometimes (OR 1.22; 95% CI: 1.05-1.43), poorer function (HAQ) (OR 1.13; 95% CI: 1.02-1.24), use of NSAID (OR 1.32; 95% CI 1.17-1.50), weak (OR 1.21; 95% CI 1.05-1.41) but not strong opioids, and less prevalent in current smokers (OR 0.76; 95%: CI 0.63-0.91). CM use was not associated with pain, disease activity, or quality of life. The most common CMs were fish oils (<i>N</i> = 1,489 users) followed by glucosamine (<i>N</i> = 605). Both declined in use over time between 2006 and 2016 (27.5% to 21.4%, trend <i>p</i> = 0.85 and 15.5% to 6.4%, trend <i>p</i> < 0.01), respectively.</p><p><strong>Conclusion: </strong>Oral CM use is common among Australians with inflammatory arthritis. Its use is greater among women and those with tertiary education. Fish oil and glucosamine, the most common CMs, both declined in use over time.</p>","PeriodicalId":51715,"journal":{"name":"International Journal of Rheumatology","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2020-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/6542965","citationCount":"6","resultStr":"{\"title\":\"Oral Complementary Medicine Use among People with Inflammatory Arthritis: An Australian Rheumatology Association Database Analysis.\",\"authors\":\"Ashley Fletcher,&nbsp;Marissa Lassere,&nbsp;Lyn March,&nbsp;Catherine Hill,&nbsp;Graeme Carroll,&nbsp;Claire Barrett,&nbsp;Rachelle Buchbinder\",\"doi\":\"10.1155/2020/6542965\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To describe oral complementary medicine (CM) use in people with inflammatory arthritis, associations with use, and changes in use over time.</p><p><strong>Methods: </strong>Demographic, clinical, and patient-reported outcome data from 5,630 participants with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), and juvenile idiopathic arthritis (JIA) were extracted from the Australian Rheumatology Association Database (ARAD), a national observational database. CM use at entry into ARAD was ascertained for participants recruited between 2002 and 2018. CM was categorised according to the NIH/Cochrane schema (fatty acids, herbs, or supplements). Logistic regression was used to assess associations between demographic characteristics and CM use. Change in CM use between 2006 and 2016 was investigated using a nonparametric test for trend of rate by year.</p><p><strong>Results: </strong>2,156 (38.3%) ARAD participants were taking CM at enrolment (RA: 1,502/3,960 (37.9%), AS: 281/736 (38.2%), PsA: 334/749 (44.6%), and JIA: 39/185 (21.1%)). CM use was more prevalent in women (OR 1.3; 95% CI: 1.13-1.50), those with tertiary education (OR 1.32; 95% CI: 1.13-1.55), private health insurance (OR 1.26; (95% CI: 1.10-1.44), drinking alcohol sometimes (OR 1.22; 95% CI: 1.05-1.43), poorer function (HAQ) (OR 1.13; 95% CI: 1.02-1.24), use of NSAID (OR 1.32; 95% CI 1.17-1.50), weak (OR 1.21; 95% CI 1.05-1.41) but not strong opioids, and less prevalent in current smokers (OR 0.76; 95%: CI 0.63-0.91). CM use was not associated with pain, disease activity, or quality of life. The most common CMs were fish oils (<i>N</i> = 1,489 users) followed by glucosamine (<i>N</i> = 605). Both declined in use over time between 2006 and 2016 (27.5% to 21.4%, trend <i>p</i> = 0.85 and 15.5% to 6.4%, trend <i>p</i> < 0.01), respectively.</p><p><strong>Conclusion: </strong>Oral CM use is common among Australians with inflammatory arthritis. Its use is greater among women and those with tertiary education. Fish oil and glucosamine, the most common CMs, both declined in use over time.</p>\",\"PeriodicalId\":51715,\"journal\":{\"name\":\"International Journal of Rheumatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2020-06-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2020/6542965\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Rheumatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2020/6542965\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2020/6542965","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 6

摘要

目的:描述口服补充药物(CM)在炎症性关节炎患者中的使用,与使用的关联,以及随时间的使用变化。方法:从澳大利亚风湿病协会数据库(ARAD)中提取5630名类风湿关节炎(RA)、强直性脊柱炎(AS)、银屑病关节炎(PsA)和青少年特发性关节炎(JIA)患者的人口统计学、临床和患者报告的结果数据。确定了2002年至2018年期间招募的参与者进入ARAD时的CM使用情况。CM根据NIH/Cochrane模式(脂肪酸、草药或补充剂)进行分类。Logistic回归用于评估人口学特征与CM使用之间的关系。2006年至2016年间,CM使用的变化情况采用逐年非参数检验。结果:2156名(38.3%)ARAD参与者在入组时服用CM (RA: 1,502/3,960 (37.9%), AS: 281/736 (38.2%), PsA: 334/749 (44.6%), JIA: 39/185(21.1%))。CM的使用在女性中更为普遍(OR为1.3;95% CI: 1.13-1.50),受过高等教育的人(OR 1.32;95% CI: 1.13-1.55),私人健康保险(OR: 1.26;(95% CI: 1.10-1.44),有时饮酒(OR: 1.22;95% CI: 1.05-1.43),功能较差(HAQ) (OR 1.13;95% CI: 1.02-1.24),使用非甾体抗炎药(OR 1.32;95% CI 1.17-1.50),弱(OR 1.21;95% CI 1.05-1.41),但不是强阿片类药物,并且在当前吸烟者中发病率较低(OR 0.76;95%: ci 0.63-0.91)。CM的使用与疼痛、疾病活动或生活质量无关。最常见的CMs是鱼油(N = 1489),其次是氨基葡萄糖(N = 605)。在2006年至2016年期间,两者的使用率分别下降(27.5%至21.4%,趋势p = 0.85; 15.5%至6.4%,趋势p < 0.01)。结论:口服CM在澳大利亚炎性关节炎患者中较为常见。它在女性和受过高等教育的人中使用得更多。鱼油和葡萄糖胺是最常见的CMs,随着时间的推移,它们的使用量都在下降。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Oral Complementary Medicine Use among People with Inflammatory Arthritis: An Australian Rheumatology Association Database Analysis.

Objectives: To describe oral complementary medicine (CM) use in people with inflammatory arthritis, associations with use, and changes in use over time.

Methods: Demographic, clinical, and patient-reported outcome data from 5,630 participants with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), and juvenile idiopathic arthritis (JIA) were extracted from the Australian Rheumatology Association Database (ARAD), a national observational database. CM use at entry into ARAD was ascertained for participants recruited between 2002 and 2018. CM was categorised according to the NIH/Cochrane schema (fatty acids, herbs, or supplements). Logistic regression was used to assess associations between demographic characteristics and CM use. Change in CM use between 2006 and 2016 was investigated using a nonparametric test for trend of rate by year.

Results: 2,156 (38.3%) ARAD participants were taking CM at enrolment (RA: 1,502/3,960 (37.9%), AS: 281/736 (38.2%), PsA: 334/749 (44.6%), and JIA: 39/185 (21.1%)). CM use was more prevalent in women (OR 1.3; 95% CI: 1.13-1.50), those with tertiary education (OR 1.32; 95% CI: 1.13-1.55), private health insurance (OR 1.26; (95% CI: 1.10-1.44), drinking alcohol sometimes (OR 1.22; 95% CI: 1.05-1.43), poorer function (HAQ) (OR 1.13; 95% CI: 1.02-1.24), use of NSAID (OR 1.32; 95% CI 1.17-1.50), weak (OR 1.21; 95% CI 1.05-1.41) but not strong opioids, and less prevalent in current smokers (OR 0.76; 95%: CI 0.63-0.91). CM use was not associated with pain, disease activity, or quality of life. The most common CMs were fish oils (N = 1,489 users) followed by glucosamine (N = 605). Both declined in use over time between 2006 and 2016 (27.5% to 21.4%, trend p = 0.85 and 15.5% to 6.4%, trend p < 0.01), respectively.

Conclusion: Oral CM use is common among Australians with inflammatory arthritis. Its use is greater among women and those with tertiary education. Fish oil and glucosamine, the most common CMs, both declined in use over time.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.40
自引率
0.00%
发文量
9
审稿时长
24 weeks
期刊最新文献
An Observational Study on the Clinical Characteristics and Prognosis of Patients With Interstitial Lung Disease Secondary to Dermatomyositis and Antisynthetase Syndrome. Exploring the Psychiatric Manifestations of Primary Sjögren’s Syndrome: A Narrative Review Association of Baseline Serum Soluble Tumour Necrosis Factor Receptor Levels with the Response of Rheumatoid Arthritis to Janus Kinase Inhibitor Therapy. Primary Immune Thrombocytopenic Purpura (ITP) and ITP Associated with Systemic Lupus Erythematosus: A Review of Clinical Characteristics and Treatment Modalities Association of Cytokine IL-17, IL-4, IL-6, and IL-12 Gene Polymorphisms in Rheumatoid Arthritis Patients in a Tertiary Care Hospital in Bangladesh.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1